Q2 2026 Myasthenia Gravis Market Advanced With Expanded Approvals and New Clinical Data

Regeneron highlighted positive clinical activity for cemdisiran and educational efforts in gMG.

Teva introduced a new HCP campaign supporting Epysqli’s availability.

Alexion shared positive clinical updates and featured new gefurulimab research.

Johnson & Johnson presented long-term clinical data for Imaavy.

Argenx announced an expanded FDA approval, launched a new Vyvgart campaign, and presented clinical data.